Author: Newsdesk

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) — Retail Opportunity Investments Corp. (NASDAQ:ROIC) announced today that Capital Finance International (CFI.co), a London-based financial news organization, has presented ROIC with its 2020 award for Best Retail REIT (U.S.).

According to CFI.co’s announcement, the award reflects ROIC’s strategic vision, resilient spirit, and a corporate culture marked by the care that the company shows customers, employees, communities and the planet. CFI.co also commended ROIC for its ongoing ESG-focused initiatives.

Stuart A. Tanz, President and Chief Executive Officer of Retail Opportunity Investments Corp. stated, “We are gratified to have earned CFI.co’s award and believe it reflects our long-standing commitment to operating responsibly and sustainably, as well as the strong relationships that we have fostered in the communities that our necessity-based shopping centers serve.”

ABOUT RETAIL OPPORTUNITY INVESTMENTS CORP.

Retail Opportunity Investments Corp. (NASDAQ: ROIC), is a fully-integrated, self-managed real estate investment trust (REIT) that specializes in the acquisition, ownership and management of grocery-anchored shopping centers located in densely-populated, metropolitan markets across the West Coast. As of September 30, 2020, ROIC owned 88 shopping centers encompassing approximately 10.1 million square feet. ROIC is the largest publicly-traded, grocery-anchored shopping center REIT focused exclusively on the West Coast. ROIC is a member of the S&P SmallCap 600 Index and has investment-grade corporate debt ratings from Moody’s Investor Services, Standard & Poor’s, and Fitch Ratings, Inc. Additional information is available at: www.roireit.net.

When used herein, the words “believes,” “anticipates,” “projects,” “should,” “estimates,” “expects,”
“
guidance
” and similar expressions are intended to identify forward-looking statements with the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and in Section 21F of the Securities and Exchange Act of 1934, as amended. Certain statements contained herein may constitute
“
forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of ROIC to differ materially from future results expressed or implied by such forward-looking statements. Information regarding such risks and factors is described in ROIC’s filings with the SEC, including its most recent Annual Report on Form 10-K, which is available at:
www.roireit.net
.

Contact:
Carol Merriman, Investor Relations
858-255-7426
[email protected]

Source: Retail Opportunity Investments Corp.

NOT FOR DISTRIBUTION TO
U.S.
NEWSWIRE SERVICES
OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — Skeena Resources Limited (TSX: SKE, OTCQX: SKREF) (“Skeena” or the “Company”) is pleased to announce that it has closed its previously announced overnight marketed public offering (the “Offering”). Pursuant to the Offering, Skeena issued 19,574,468 common shares of the Company (the “Common Shares”), including 2,553,191 Common Shares issued in connection with the exercise in full of the over-allotment option granted to the Underwriters (as defined below) in connection with the Offering, at a price of C$2.35 per Common Share for gross proceeds of C$46.0 million.

The Offering was completed through a syndicate of underwriters co-led by Raymond James Ltd. and Canaccord Genuity Corp., and including Clarus Securities Inc., Sprott Capital Partners and RBC Capital Markets (collectively the “Underwriters”).

The Common Shares were offered pursuant to a final prospectus supplement dated November 11, 2020 to the Company’s short form base shelf prospectus dated November 4, 2020. The Common Shares were offered in each of the provinces of Canada, except Québec. The Common Shares were sold to U.S. buyers on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended, and other jurisdictions outside of Canada provided that no prospectus filing or comparable obligation arises.

The net proceeds of the Offering will be used by the Company to fund ‎exploration and development activities at the Eskay Creek Project and Snip Gold Project, and for general ‎administrative and corporate purposes.

Agentis Capital Mining Partners, Jett Capital Advisors, and Tectonic Advisory Partners have acted has financial advisors to the Company.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Skeena

Skeena Resources Limited is a junior mining company focused on developing the past-producing Eskay Creek gold-silver mine located in Tahltan Territory in the Golden Triangle of northwest British Columbia, Canada. The Company released a robust Preliminary Economic Assessment in late 2019 and is currently focused on infill and exploration drilling at Eskay Creek to advance the project to Prefeasibility. Skeena is also exploring the past-producing Snip gold mine.

On behalf of the Board of Directors of Skeena Resources Limited,

Walter Coles Jr.
President & CEO

Cautionary note regarding forward-looking statements
Certain statements made and information contained herein may constitute “forward looking information” and “forward looking statements” within the meaning of applicable Canadian and United States securities legislation. These statements and information are based on facts currently available to the Company and there is no assurance that actual results will meet management’s expectations. Forward-looking statements and information may be identified by such terms as “anticipates”, “believes”, “targets”, “estimates”, “plans”, “expects”, “may”, “will”, “could” or “would”. In this new release, forward-looking statements relate to, among other things: the use of the net proceeds therefrom; anticipated advancement of the Eskay Creek Project and the Snip Project; and future exploration and development plans of Skeena.

Forward-looking statements and information contained herein are based on certain factors and assumptions regarding, among other things, the estimation of mineral resources and reserves, the realization of resource and reserve estimates, metal prices, taxation, the estimation, timing and amount of future exploration and development, capital and operating costs, the availability of financing, the receipt of regulatory approvals, environmental risks, title disputes and other matters. While the Company considers its assumptions to be reasonable as of the date hereof, forward-looking statements and information are not guarantees of future performance and readers should not place undue importance on such statements as actual events and results may differ materially from those described herein. The Company does not undertake to update any forward-looking statements or information except as may be required by applicable securities laws.

Neither the Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Walter Coles Jr.
President & CEO
Office: 604 684 8725
[email protected]

Trusted by Hospitals and Restaurants,
PlayArmor
Provid
es
a Long-Lasting
Antimicrobial Biostatic Finish
That
Neutraliz
es
Microbes

• PlayArmor is available
  now
  for use
  exclusively on PlayPower’s brands of indoor and outdoor play equipment
  ,
  and in early 202
  1
  for its
  treated site amenities such as picnic tables and benches
• Cleaning with a disinfectant only lasts until the next person touches the equipment;
  registered with
  the U.S. Environmental Protection Agency, PlayArmor takes safety to the next level,
  with no need to reapply
  for
  up to
  90 days to
  help
  protect
  playgrounds and site furnishings
  between
  cleanings
• With m
  any playgrounds closed temporarily due to
  the
  pandemic
  ,
  the company launched PlayArmor
  to help create an even safer environment as
  playgrounds
  reopen   

HUNTERSVILLE, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) — PlayPower, the world’s largest commercial playground and recreational equipment manufacturer, today introduced PlayArmor^™, a long-lasting antimicrobial coating specifically targeted for use on playgrounds to add a barrier of protection to the surfaces that children touch. PlayArmor is available in the U.S. for exclusive use on PlayPower’s brands of indoor and outdoor play equipment.

Registered with the U.S. Environmental Protection Agency (EPA), PlayArmor is based on well-established technology that’s scientifically proven to create an effective, safe and active surface barrier.

“PlayPower has a legacy of doing things the right way, so the safety of our brand product lines — and of play itself — is always our priority,” said Todd Brinker, PlayPower senior vice president of sales and marketing for outdoor play. “At the onset of the COVID-19 pandemic, we began talking to customers about how we could help keep their play equipment safe. We set a goal to make play environments as germ-free as possible and PlayArmor is the result of that focused effort.”

PlayPower is the exclusive distributor for Clearstream^® Technologies, the specialized chemical company that makes PlayArmor for application on commercial playgrounds and site amenities, such as picnic tables and benches. No other playground equipment manufacturer has access to the PlayArmor brand.

Representatives for the PlayPower brands Little Tikes Commercial^®, Miracle^®, Playworld^®, and Soft Play^® will make PlayArmor available for application to existing and newly purchased play equipment after installation. PlayPower brand Wabash Valley, makers of high-end commercial site furnishings, will begin coating new products during manufacturing in the first quarter of 2021.

PlayArmor, which bonds to the playground surface, remains effective for its intended purpose for up to 75 pressure washes. PlayPower recommends reapplication every 90 days, which maximizes product surface protection throughout the year.

“Whether indoors or outdoors, it’s impossible to keep playgrounds germ-free just with daily cleaning and disinfection, because they are only effective until the next child or parent touches the equipment,” said Ken Schober, vice president of PlayPower’s indoor play division. “PlayArmor helps protect surfaces between cleanings.”

PlayPower will offer commercial-grade labels that let visitors know the playground has been treated with PlayArmor. The labels will also direct people to further information about the antimicrobial coating via a website link or QR code.

PlayArmor is safe for contact with humans, animals and the environment. The technology is used throughout hospitals, including in surgical theaters, isolation wards, medical research facilities and intensive care units.

For more information about PlayArmor, visit www.PlayArmor.com.

About PlayArmor
^™

The active ingredient in PlayArmor is categorized as a silane quaternary ammonium. This is a well-established class of antimicrobials that enact a “mechanical kill” of pathogens rather than a “chemical kill.” In effect, PlayArmor penetrates the cell wall of the pathogen, killing it by rupturing the cell membrane. Other antimicrobials on the market poison cells to kill them, creating the potential for antimicrobial-resistant superbugs. That is not possible with PlayArmor. PlayArmor does not protect against airborne transmission of viruses. Therefore, mask wearing, social distancing and other protective measures are still recommended during indoor and outdoor play. www.PlayArmor.com

About PlayPower

^®


PlayPower, Inc. is a leading manufacturer of outdoor recreational products and is the world’s largest, fully integrated manufacturer of commercial playground equipment, surfacing solutions, floating dock systems and lifts for boats and personal watercraft, shade solutions and site furnishings. The company is headquartered in Huntersville, North Carolina, with offices and manufacturing facilities in Monett, Missouri; Lewisburg, Pennsylvania; Englewood, Colorado; Dallas, Texas; Nogales, Mexico; Selby, England; Perth, Scotland; Sosnowiec, Poland; and Aneby, Sweden. PlayPower’s goal is to lead the market in all areas in which it competes and to continue to bring innovation and fun to the marketplace. The Company’s website is www.PlayPower.com.

Media Contact:
Jennifer Leckstrom
RoseComm for PlayPower
[email protected]
215-681-0770

TEMPE, Ariz., Nov. 17, 2020 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (the “Company” or “Wrap”) (Nasdaq: WRTC), an innovator of modern policing solutions, announced today 4 key additions to the Company’s inside and outside sales teams, including Directors of Western Regional Sales and Eastern Regional Sales.

“We are excited to be introducing additional talent to our sales department,” said Tom Smith, President and Interim CEO of Wrap Technologies. “We continue to see a strong pipeline of inbound requests for BolaWrap demonstrations, training and quotes, and many agencies who have previously seen demos or have been trained on the BolaWrap are now beginning to outfit their officers with our device.”

“With 13 distributors across the US covering 49 states and a majority of domestic sales coming through our distribution network, it is important that we continue to grow in our ability to support our distributors and help drive volume.”

Recent orders from domestic law enforcement agencies received and expected to ship this quarter include:

• Agency in Indiana: purchased 25 devices
• Agency in Ohio: purchased 15 devices
• Agency in Texas: purchased 10 devices
• Agency in Michigan: purchased 10 devices

Additionally, initial small orders were received from agencies in Georgia, Minnesota, Virginia, Illinois, Arkansas, New York, Maine, several Universities and a Federal agency. We expect these orders may lead to additional future orders.

About Wrap Technologies (WRTC)
Wrap Technologies is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wrap.com.

Follow WRAP® here:

WRAP on Facebook: https://www.facebook.com/wraptechnologies/
WRAP on Twitter: https://twitter.com/wraptechinc
WRAP on LinkedIn: https://www.linkedin.com/company/wraptechnologiesinc/

Trademark Information
BolaWrap and Wrap are trademarks of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement  
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Wrap Technologies, Inc.

Paul M. Manley
VP – Investor Relations
(612) 834-1804
[email protected]

Arlington, Va., Nov. 17, 2020 (GLOBE NEWSWIRE) — The American Institutes for Research (AIR), one of the world’s leading behavioral research organizations, has acquired Kimetrica LLC, an international consulting firm that provides research and evaluation, surveys, information management, and modeling and simulation expertise to clients around the globe.

AIR, a not-for-profit founded in 1946, works with government agencies, philanthropies and other organizations to conduct research and evaluation and provide technical assistance in the areas of education, health and workforce development, in the U.S. and abroad. While AIR has a strong presence in the international sector, Kimetrica conducts work in areas where AIR is seeking to grow, including nutrition, health, food security, and famine early warning systems. Kimetrica, founded in 2006, also has expertise in leveraging the latest technology to address the needs of their clients, including software development, data science and analytics, and machine learning. 

“Kimetrica is conducting important, innovative work to address some of the most complex challenges facing the world today and AIR is excited to have them as a part of our team,” said David Myers, AIR’s President and CEO. “This acquisition will allow us to better provide a full range of services to international clients—from identifying and quantifying problems through rigorous research and evaluation, to working with governments and other organizations to develop, implement and test solutions that address those challenges and create a better, more equitable world.”

Kimetrica, with 70 employees, has performed work in more than 50 countries. Some of their largest clients include the U.S. Agency for International Development (USAID), the Defense Advanced Research Projects Agency (DARPA), UNICEF, the World Bank, the United Nations, and others. Kimetrica has headquarters in Broomfield, Colorado, and offices in Washington, D.C.; Nairobi, Kenya; and Addis Ababa, Ethiopia.

This transaction allows Kimetrica to join a company with a similar mission-focus and shared values that can amplify the awareness and impact of the company’s work and technology solutions.

Kimetrica CEO Ben Watkins said that “From day one, AIR seemed like the best possible partner. Our visions and ethos are totally aligned. By partnering with a larger organization, we can reach a wider audience and have the opportunity to apply our technologies to new and exciting situations.”

AIR’s current international development work covers a broad range of topics, including education systems and programs; international assessments and surveys; agriculture; social protection; water and sanitation; women’s groups; and the health and well-being of refugee and migrant populations. Clients of AIR’s international practice include UNICEF, USAID, the Millennium Challenge Corporation, the Bill & Melinda Gates Foundation, and others.

AIR recently acquired IMPAQ, LLC, which also conducts international research and technical assistance, across several areas, including agriculture, education and training, labor and more.

“With Kimetrica and IMPAQ as a part of AIR, we are well positioned to provide a full range of monitoring, research, evaluation, and technical assistance services to help reduce inequality globally,” said AIR Vice President David Seidenfeld, who leads AIR’s International Development Division.  

About AIR

Established in 1946, the American Institutes for Research (AIR) is a nonpartisan, not-for-profit organization that conducts behavioral and social science research and delivers technical assistance both domestically and internationally in the areas of education, health and the workforce. AIR’s work is driven by its mission to generate and use rigorous evidence that contributes to a better, more equitable world. With headquarters in Arlington, Virginia, AIR has offices across the U.S. and abroad. For more information, visit www.air.org.

About Kimetrica

Kimetrica provides research, evaluation, survey, information management, and modeling and simulation services for evidence-based decision-making and learning. Kimetrica works with governments and non-profit organizations to increase the impact and efficiency of their social investments, enhance accountability, manage critical risks, and build donor or taxpayer confidence. Kimetrica has successfully managed IDIQ mechanisms and more than 100 analytical and support activities, primarily in East Africa, but also around the world. For more information, visit www.kimetrica.com.

Attachments

• AIR-Kimetrica-logo-Nov2020
• AIR-Kimetrica-Fact Sheet-Nov2020

Dana Tofig
American Institutes for Research
202-403-6347
[email protected]

Vancouver, B.C., Nov. 17, 2020 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (“Lomiko”) (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) is focused on the exploration and development of flake graphite in Quebec for the new green economy.  Lomiko is pleased to announce the Board of Directors has formed a Technical, Safety, and Sustainability Committee (“LTSSC”), reporting to the Board of Directors.  At the time of formation, the LTSCC is comprised of A. Paul Gill, CEO, and two Independent Directors, Gabriel Erdelyi and Julius Galik.

 

LTSSC Committee Responsibilities

 

The LTSSC will oversee the assessment of the La Loutre Flake Graphite Property, and liaise with service providers, technical staff and stakeholders to put forward a series of crucial technical documents including, but not limited to, a Scope of Work (SOW), Graphite Characterization and Metallurgy, Response for Proposal (RFP) on a Preliminary Economic Assessment, and, if required, pre-feasibility, bulk samples, pilot plant, feasibility and construction plans.  The Committee will govern the hiring of technical staff, liaise with extra-company agencies and representatives, and provide a conduit to the Board of Directors to make crucial decisions on the project.

 

Further additions to the Committee and the Lomiko team are anticipated and will be announced when confirmed.

 

Lomiko’s Near Term Goals

 

Graphite demand is expected to increase exponentially for the mined natural graphite material, as more is used in the production of spherical graphite for graphite in the anode portion of Electric Vehicle Lithium-ion batteries.

 

Lomiko completed a $ 750,000 financing October 23, 2020 and plans to work on its near-term goals:

 

1) Complete 100% Acquisition of the Property, currently 80% owned by Lomiko Metals.

 

2) Complete metallurgy and graphite characterization to confirm li-ion anode grade material.

 

3) Complete a Technical Report to confirm that the extent of the mineralization equals or surpasses the nearby Imerys Mine, owned by an international mining conglomerate.

 

A “technical report” means a report prepared and filed in accordance with this Instrument and Form 43-101F1 Technical Report, and includes, in summary form, all material scientific and technical information in respect of the subject property as of the effective date of the technical report;

 

4) Complete Preliminary Economic Assessment (PEA)

 

A PEA means a study, other than a pre-feasibility or feasibility study, that includes an economic analysis of the potential viability of mineral resources.

 

For more information on Lomiko Metals, Promethieus, review the website at www.lomiko.com, and www.promethieus.com, contact A. Paul Gill at 604-729-5312 or email: [email protected].

 

On Behalf of the Board

 

“A. Paul Gill”

 

Director, Chief Executive Officer

 

We seek safe harbor.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accept responsibility for the adequacy or accuracy of this release.

Attachment

• supply-demand curve for graphite

A. Paul Gill
Lomiko Metals Inc. (TSX-V: LMR)
6047295312
[email protected]

* Dr. Schwartz Served as ArQule’s Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 *

Nes Ziona, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that Brian Schwartz, MD, who served for twelve years as Chief Medical Officer of ArQule, Inc. and led ArQule’s research and development programs through its $2.7 billion acquisition by Merck earlier this year, joined the Enlivex Board of Directors on November, 15, 2020.

Dr. Schwartz commented, “I am excited to be joining the Board of Directors of Enlivex. After carefully reviewing the scientific basis and data for Allocetra^TM, which is currently in clinical development for sepsis and COVID-19, and in preclinical development for solid cancers, I believe that this innovative immunotherapy approach has the potential to significantly impact life-threatening, high-mortality diseases. Additionally, I believe that the planned and ongoing clinical program, coupled with a management team that has a track-record of creating shareholder value, leaves the Company well positioned for sustained near- and long-term growth.”

Dr. Schwartz brings significant experience in drug development in both the biotechnology and pharmaceutical industries. Dr. Schwartz most recently served as Chief Medical Officer and head of Research and Development of ArQule, Inc. where he served as a key member of the management team and spearheaded a number of preclinical and clinical drug development programs in oncology and rare diseases. Prior to joining ArQule in 2008, Dr. Schwartz served as Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm Oncology, Inc., where he built and led clinical, regulatory, and quality assurance departments responsible for the development of new cancer drugs. Earlier in his career, Dr. Schwartz held a number of positions at Bayer Healthcare and Leo Laboratories. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and has extensive regulatory experience working with the FDA’s Oncology Division, the European Medicines Evaluation Agency (EMEA), and numerous other health authorities. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in the biopharmaceutical industry. Dr Schwartz is currently serves as a board member of Mereo Biopharma and LifeSci Acquisition Corp.

Shai Novik, Executive Chairman of the Board of Enlivex, stated, “We are excited to have Dr. Schwartz on our Board. He has significant relevant experience in all aspects of the product development lifecycle and shareholder value creation. We look forward to working together.”     

ABOUT ENLIVEX

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and COVID-19, as well as enhancement of immune activity against solid tumors in combination with CAR-T or immune checkpoint therapies.

For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA^TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT                                                                            
Shachar Shlosberger, CFO                                                                    
Enlivex Therapeutics, Ltd.                                                                      
[email protected]

INVESTOR RELATIONS CONTACT

Eric Ribner
LifeSci Advisors
[email protected]